Ken Takeshita, Daiichi Sankyo R&D chief

En­her­tu nabs pri­or­i­ty re­view for NSCLC as As­traZeneca and Dai­ichi Sankyo con­tin­ue chart­ing a block­buster course

As As­traZeneca and Dai­ichi Sankyo con­tin­ue to out­line their block­buster plans for the an­ti­body-drug con­ju­gate En­her­tu, the FDA is giv­ing them an as­sist.

Reg­u­la­tors award­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.